Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
https://www.zacks.com/stock/news/2240974/biotech-stock-roundup-amlx-acad-down-on-study-data-mrna-rgls-gain-on-updates-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2240974
Mar 14, 2024 - Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
0
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2212223/sana-bio-sana-stock-rallies-105-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2212223
Jan 18, 2024 - Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
0
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
https://www.zacks.com/stock/news/2210929/what-s-in-store-for-thermo-fisher-tmo-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2210929
Jan 16, 2024 - Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.
0
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
https://www.zacks.com/stock/news/2208247/atea-pharma-avir-gains-on-upbeat-initial-data-from-hcv-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208247
Jan 10, 2024 - Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
0
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
https://www.zacks.com/stock/news/2207561/novo-nordisk-s-nvo-phase-iii-diabetes-study-meets-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207561
Jan 09, 2024 - Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
0
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
https://www.zacks.com/stock/news/2207159/exelixis-exel-posts-preliminary-2023-results-to-cut-13-jobs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207159
Jan 08, 2024 - Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
0
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
https://www.zacks.com/stock/news/2203852/acadia-s-acad-nuplazid-sales-drive-growth-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2203852
Dec 29, 2023 - Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
0
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198026
Dec 14, 2023 - bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
0
Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid
https://www.zacks.com/stock/news/2197873/acadia-acad-rises-35-on-positive-patent-ruling-for-nuplazid?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197873
Dec 14, 2023 - Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.
0
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
https://www.zacks.com/stock/news/2192952/is-gsk-plc-sponsored-adr-gsk-stock-outpacing-its-medical-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2192952
Dec 04, 2023 - Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
0
Pages: 12
Page 1